Clinical and Experimental Rheumatology | |
Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab. | |
A. Perin1  S. De Vita1  E. Di Poi1  M. Del Frate1  G.F. Ferraccioli1  M.P. Morassi1  | |
关键词: Rheumatoid arthritis; etanercept; infliximab; efficacy.; | |
DOI : | |
学科分类:医学(综合) | |
来源: Pacini Editore SpA | |
【 摘 要 】
ABSTRACT: TNF-α is thought to play a pivotal role in the initiation and perpetuation of the chronic inflammatory process in rheumatoid arthritis.TNF-α blockers such as infliximab and etanercept are currently used in the treatment of active rheumatoid arthritis (RA) when traditional DMARDs have failed and are effective in a significant proportion of patients. However, about one third are non-responders to anti-TNF-α.The aim of this study was to verify whether rheumatoid patients, after failing infliximab, can benefit from etanercept.We analysed 18 patients with active RA with no response to at least 3 DMARDs and where infliximab therapy had failed. The patients had received infliximab associated with methotrexate: eleven of them did not show any significant response, while seven patients, after a good response, relapsed. Etanercept was then started. EULAR criteria of response were used with calculation of activity index DAS28 at baseline, after 2 weeks, 3 months and every third month until last follow-up. A moderate or good response was achieved with etanercept in 13 out of 18 patients. From our experience, etanercept can be considered as a good alternative choice when infliximab has failed.
【 授权许可】
Unknown
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO201912020416097ZK.pdf | 512KB | download |